- ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
- ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
- ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
- ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
- ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
- ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
- ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.48 |
---|---|
High | 11.27 |
Low | 10.16 |
Bid | 10.24 |
Offer | 10.50 |
Previous close | 9.96 |
Average volume | 1.33m |
---|---|
Shares outstanding | 96.50m |
Free float | 69.92m |
P/E (TTM) | -- |
Market cap | 986.25m USD |
EPS (TTM) | -0.5719 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼